The FDA has granted approval to a subcutaneous formulation of mosunetuzumab (Lunsumio VELO; Genentech/Roche) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma ...

The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and ...

Through genetic analysis and precision IV therapy, 10X Health and REVIV are shifting beauty standards from external fixes to ...

I came across an interesting article about the "longevity doctor" Mohammed Enayats who claims to have cut his biological age from 41 to 24, while plugging treatments at his Chelsea-based "futuristic h ...

A golden retriever, a golden doodle, a terrier, a spaniel. How these pups are making kids feel better in Southwest Florida.

During a live event, Hannah Choe, MD, analyzed key findings from the AGAVE-201 trial of axatilimab in chronic graft-vs-host disease. A significant number of patients who develop chronic graft-vs-host ...

The FDA granted accelerated approval to Lunsumio VELO for adults with relapsed/refractory follicular lymphoma after two or ...

For many people, especially those dealing with chronic stress or low energy, conventional health care feels reactive and slow. Retail IV clinics offer immediacy, personalized attention, and a sense of ...

As a rare but alarming outbreak of infant botulism linked to contaminated baby formula spread across the U.S., Health Writer JoNel Aleccia delivered the ...

J&J has received the US FDA approval for Rybrevant Faspro, a SC administered therapy to treat patients with EGFR-mutated ...

The green light for Rybrevant Faspro – which combines amivantamab with hyaluronidase – means that the drug is the first ...

The FDA approves a new subcutaneous formulation of amivantamab, enhancing treatment for advanced lung cancer with reduced administration time and improved safety.